Article
Clinical Neurology
Pim B. van der Meer, Linda Dirven, Marta Fiocco, Maaike J. Vos, Mathilde C. M. Kouwenhoven, Martin J. van den Bent, Martin J. B. Taphoorn, Johan A. F. Koekkoek
Summary: This retrospective observational study found that levetiracetam may have better efficacy compared to valproic acid for patients with glioma and epilepsy, while the toxicity levels seem similar between the two drugs. Therefore, levetiracetam appears to be the preferred choice for first-line antiepileptic drug treatment in glioma patients.
Article
Clinical Neurology
Johan Pallud, Gilles Huberfeld, Edouard Dezamis, Sophie Peeters, Alessandro Moiraghi, Martine Gavaret, Eleonore Guinard, Frederic Dhermain, Pascale Varlet, Catherine Oppenheim, Fabrice Chretien, Alexandre Roux, Marc Zanello
Summary: This study suggests that the use of levetiracetam during the standard chemoradiation protocol may improve the overall survival of patients with IDH wild-type glioblastoma.
Article
Clinical Neurology
Sam Fairclough, John Goodden, Paul Chumas, Ryan Mathew, Melissa Maguire
Summary: This study aims to identify factors that influence the probability of seizure freedom and treatment failure in patients with WHO grade 2 glioma. The results show that using levetiracetam as a first-line antiseizure medication significantly increases the probability of seizure freedom at 2 years. Patients with mainly focal seizures without progression have a significantly lower chance of achieving seizure freedom within 10 years.
Review
Neurosciences
Kate E. Hills, Kostas Kostarelos, Robert C. Wykes
Summary: Glioblastoma is the most common and advanced malignant tumor in the adult central nervous system, often associated with epilepsy. The interaction between glioblastoma and epilepsy promotes the progression of both pathologies through various mechanisms, including molecular mutations, blood-brain barrier breakdown, and dysregulation of neurotransmitters. Understanding these mechanisms is crucial for the treatment of glioblastoma-related epilepsy.
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Andra V. Krauze, Yingdong Zhao, Ming-Chung Li, Joanna Shih, Will Jiang, Erdal Tasci, Theresa Cooley Zgela, Mary Sproull, Megan Mackey, Uma Shankavaram, Philip Tofilon, Kevin Camphausen
Summary: The addition of VPA to standard CRT treatment for GBM leads to differential alterations in proteomic expression pre- vs. post-completion of concurrent chemoirradiation, potentially influencing patient outcomes. The identified protein signals and hallmark gene sets associated with VPA treatment align with known biological pathways, providing insight into the mechanisms of action and potential biomarkers for future studies.
Article
Clinical Neurology
Makihiko Nagano, Takashi Tagami, Junya Kaneko, Masayoshi Kondo, Mio Hotta, Minoru Kubota, Kazutoshi Sugaya, Hisamitsu Takase, Masamune Kuno, Kyoko Unemoto
Summary: This study aimed to evaluate the blood concentration of levetiracetam in patients with status epilepticus in an emergency clinical setting. The results showed that levetiracetam reached therapeutic levels in patients with early-stage status epilepticus after a bolus administration of 2500 mg, with positive effects observed in secondary outcomes.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
(2021)
Review
Clinical Neurology
Elisaveta Sokolov, Jorg Dietrich, Andrew J. Cole
Summary: Seizures are a common clinical sign in people with glioblastoma. Recent advances in understanding the pathophysiology of epilepsy in these patients have shed light on the causes, clinical manifestations, and implications for management. Successful management of epilepsy in glioblastoma patients remains challenging, with factors such as drug interactions and side-effects affecting seizure outcomes. Further research is needed to determine the effects of novel therapies on seizures, and larger clinical trials are necessary in this field.
Article
Oncology
Franz L. Ricklefs, Richard Drexler, Kathrin Wollmann, Alicia Eckhardt, Dieter H. Heiland, Thomas Sauvigny, Cecile Maire, Katrin Lamszus, Manfred Westphal, Ulrich Schueller, Lasse Duehrsen
Summary: This study found a strong correlation between RTK II glioblastomas and preoperative and long-term seizures. The results highlight the importance of molecular glioblastoma profiling for postoperative seizure control.
Article
Oncology
Ramazan Jabbarli, Yahya Ahmadipour, Laurel Rauschenbach, Alejandro N. Santos, Marvin Darkwah Oppong, Daniela Pierscianek, Carlos M. Quesada, Sied Kebir, Philipp Dammann, Nika Guberina, Bjorn Scheffler, Klaus Kaier, Martin Stuschke, Ulrich Sure, Karsten H. Wrede
Summary: The study suggests that perioperative treatment with levetiracetam might improve overall and progression-free survival in glioblastoma patients. A meta-analysis of previous studies also confirmed the positive impact of levetiracetam on survival outcomes in individuals with glioblastoma, supporting the need for a prospective clinical trial to further evaluate its efficacy in treatment.
Article
Behavioral Sciences
Chiara Milano, Francesco Turco, Chiara Pizzanelli, Enrica Bonanni, Gabriele Siciliano, Francesco Fornai, Filippo Sean Giorgi
Summary: This study found that LEV monotherapy was significantly more effective than LTG monotherapy for patients with JME who had previously been treated with VPA monotherapy and had to discontinue VPA due to its teratogenic potential. In particular, patients who experienced seizure relapse on LTG and switched to LEV monotherapy achieved good seizure control.
EPILEPSY & BEHAVIOR
(2021)
Article
Clinical Neurology
Kristin M. Knudsen-Baas, Anette M. Storstein, Alessia Zarabla, Andrea Maialetti, Diana Giannarelli, Ettore Beghi, Marta Maschio
Summary: This study found that ES as the presenting symptom in adult GBM patients does not lead to better overall survival. LEV was more effective compared to other ASM treatments, with no significant differences in adverse events. Surprisingly, both LEV and VPA were associated with worse OS compared to other ASM treatments, but caution should be exercised in interpreting these results due to the retrospective nature of the study and multiple influencing variables.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
(2021)
Article
Medicine, General & Internal
Akira Kurishima, Mototaka Hayashi, Rin Shimozato, Ryo Isozaki, Tomoko Shioda, Akira Iijima
Summary: This case report demonstrates that both VPA and LEV can be well absorbed in the gastrointestinal tract of patients with short-bowel syndrome.
Article
Clinical Neurology
Anteneh M. Feyissa, Steven S. Rosenfeld, Alfredo Quinones-Hinojosa
Summary: Glioblastoma multiforme (GBM) is a common and aggressive brain cancer that often leads to drug-resistant seizures and cognitive impairments. Recent studies suggest that seizures and glioma have common pathogenic mechanisms and can influence each other. Elevated levels of glutamate in the tumor microenvironment (TME) are a possible explanation for the connection between these two conditions.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Emanuele Cerulli Irelli, Enrico Cocchi, Alessandra Morano, Joanna Gesche, Roberto H. Caraballo, Simona Lattanzi, Gionata Strigaro, Cecilia Catania, Edoardo Ferlazzo, Angelo Pascarella, Sara Casciato, Pierpaolo Quarato, Chiara Pizzanelli, Patrizia Pulitano, Loretta Giuliano, Veronica Viola, Barbara Mostacci, Francesco Fortunato, Carla Marini, Giancarlo Di Gennaro, Antonio Gambardella, Angelo Labate, Francesca F. Operto, Anna T. Giallonardo, Betul Baykan, Christoph P. Beier, Carlo Di Bonaventura
Summary: This study compared the effectiveness and safety of levetiracetam and lamotrigine as initial monotherapy in female patients of childbearing age with idiopathic generalized epilepsy (IGE). The study found that levetiracetam was associated with a reduced risk of treatment failure, particularly in patients with juvenile myoclonic epilepsy. However, patients treated with levetiracetam experienced more adverse effects.
Article
Pharmacology & Pharmacy
Shih-Yin Ho, Li Lin, I-Chun Chen, Che-Wen Tsai, Fang-Chia Chang, Horng-Huei Liou
Summary: The study evaluated the antiepileptic effect of the AMPA receptor antagonist perampanel (PER) on a mouse model of Dravet syndrome, showing significant therapeutic potential in reducing spontaneous recurrent seizures and improving hyperthermia-induced seizures. PER also demonstrated a synergistic effect in combination with stiripentol or valproic acid for attenuating heat-induced seizures, highlighting its potential as a treatment option for Dravet syndrome.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
M. Kerkhof, R. E. Hagenbeek, B. F. W. van der Kallen, G. J. Lycklama A. Nijeholt, L. Dirven, M. J. B. Taphoorn, M. J. Vos
EUROPEAN JOURNAL OF NEUROLOGY
(2016)
Article
Oncology
M. Kerkhof, I. Ganeff, R. G. J. Wiggenraad, G. J. Lycklama a Nijeholt, S. Hammer, M. J. B. Taphoorn, L. Dirven, M. J. Vos
JOURNAL OF NEURO-ONCOLOGY
(2018)
Article
Clinical Neurology
Melissa Kerkhof, Charles J. Vecht
Meeting Abstract
Urology & Nephrology
Melissa Kerkhot, Monique J. Roobol, Ewout W. Steyerberg, Jack Cuzick, Fritz H. Schroder
JOURNAL OF UROLOGY
(2009)
Article
Oncology
Melissa Kerkhof, Janneke C. M. Dielemans, Melanie S. van Breemen, Hanneke Zwinkels, Robert Walchenbach, Martin J. Taphoorn, Charles J. Vecht
Article
Oncology
M. Kerkhof, J. A. F. Koekkoek, M. J. Vos, M. J. van den Bent, W. Taal, T. J. Postma, J. E. C. Bromberg, M. C. M. Kouwenhoven, L. Dirven, J. C. Reijneveld, M. J. B. Taphoorn
JOURNAL OF NEURO-ONCOLOGY
(2019)